Related Experiment Videos
Acetylation as an indicator of risk
1John L. McClelian VA Hospital, Little Rock, Arkansas, USA. nplang@life.uams.edu
Environmental Health Perspectives
|June 1, 1997
Summary
Aromatic amine acetylation, a human metabolic polymorphism, impacts disease risk. Understanding N-acetyltransferase (NAT) enzyme variants is crucial for accurate individual risk assessment and exposure identification.
Area of Science:
- Pharmacogenomics
- Metabolic Polymorphisms
- Biomarker Discovery
Background:
- Aromatic amine acetylation is a well-established human metabolic polymorphism linked to various diseases.
- This system is a valuable model for risk assessment due to its role in drug/carcinogen metabolism and ease of measurement.
- Interactions between N-acetyltransferase 1 (NAT1) and NAT2 phenotypes/genotypes highlight the complexity of xenobiotic metabolism.
Purpose of the Study:
- To explore the complexity of aromatic amine acetylation in human metabolism.
- To investigate the role of NAT1 and NAT2 in disease risk assessment.
- To identify factors influencing the utility of acetylation status as a predictive biomarker.
Main Methods:
- Analysis of aromatic amine acetylation polymorphism.
- Assessment of N-acetyltransferase 1 (NAT1) and NAT2 phenotypes and genotypes.
- Evaluation of enzyme variant multiplicity in human populations.
Main Results:
- The rapid acetylation phenotype is associated with increased colon cancer risk.
- The slow acetylation phenotype is linked to increased urinary bladder cancer risk.
- Complexity arises from potential interactions between NAT1 and NAT2 variants.
Conclusions:
- Further research is needed to identify specific aromatic amine exposure sources.
- Characterizing NAT1 and NAT2 substrate specificity across human enzyme variants is essential.
- Accurate utilization of acetylation status as an individual risk predictor requires further investigation.